Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure

Aims Jugular venous distension is a classical sign of heart failure (HF) but it can be difficult to assess clinically. Methods and results Outpatients with HF and control subjects were assessed. Internal jugular vein diameter (JVD) was measured using a linear high-frequency ultrasound probe (10 MHz) at rest, after a Valsalva manoeuvre and during deep inspiration. JVD ratio was calculated as the maximum diameter during Valsalva to that measured at rest. 311 patients (mean age 71 years, mean left ventricular EF 42%, median (IQR) amino-terminal pro-brain natriuretic peptide 979 (441–2007) ng/L) and 66 controls were included. JVD (median and IQR range) at rest was smaller in controls (0.16 (0.14–0.20) cm) than in patients with HF (0.23 (0.17–0.33) cm; p<0.001) but similar during Valsalva (1.03 (0.90–1.16) cm vs 1.08 (0.90–1.25) cm; p=0.28). Consequently, JVD ratio was greater in controls (6.3 (4.9–7.6)) than in patients (4.5 (2.9–6.1); p<0.001). During a median follow-up of 516 (IQR 335–622) days, 48 patients (15%) with HF died or were hospitalised for HF. In multivariable models, among clinical, echocardiographic or biochemical variables, only increasing NT-proBNP and ultrasound assessment of internal jugular vein were independently associated with prognosis. Comparing top and bottom tertiles of JVD ratio (2.3 (IQR 1.7–2.9) versus 6.8 (6.1–7.7)), the tertile with lower values had a 10-fold greater risk of an adverse event (HR 10.05, 95% CI 3.07 to 32.93). Conclusions Ultrasound assessment of the internal jugular vein identifies outpatients with HF who have a higher risk of an adverse outcome. Clinical trial registration NCT01872299.

[1]  S. McGee Physical examination of venous pressure: a critical review. , 1998, American heart journal.

[2]  J. Cleland,et al.  Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification? , 2013, The International Journal of Cardiovascular Imaging.

[3]  R. Califf,et al.  Value of Clinician Assessment of Hemodynamics in Advanced Heart Failure: The ESCAPE Trial , 2008, Circulation. Heart failure.

[4]  J. Cleland,et al.  Assessment and diagnosis of heart failure , 1996, Journal of internal medicine.

[5]  Nick Freemantle,et al.  Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial. , 2007, European heart journal.

[6]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[7]  P. Hildebrandt,et al.  Adding serial N‐terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study) , 2013, European journal of heart failure.

[8]  J. Cleland,et al.  Does the physical examination still have a role in patients with suspected heart failure? , 2011, European journal of heart failure.

[9]  J. Cleland,et al.  Does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF? , 2014, Journal of the American College of Cardiology.

[10]  M. Drazner,et al.  Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[12]  N. Freemantle,et al.  Relationship between plasma concentrations of N‐terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP‐CHF study , 2012, European journal of heart failure.

[13]  John G F Cleland,et al.  Revisiting a classical clinical sign: jugular venous ultrasound. , 2014, International journal of cardiology.

[14]  V. Roger,et al.  Pulmonary pressures and death in heart failure: a community study. , 2012, Journal of the American College of Cardiology.

[15]  C. Schneider,et al.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. , 2008, European heart journal.

[16]  G. Bruno,et al.  N-Terminal Probrain Natriuretic Peptide Is a Stronger Predictor of Cardiovascular Mortality Than C-Reactive Protein and Albumin Excretion Rate in Elderly Patients With Type 2 Diabetes , 2013, Diabetes Care.

[17]  John G F Cleland,et al.  Remote telemonitoring for patients with heart failure: might monitoring pulmonary artery pressure become routine? , 2014, Expert review of cardiovascular therapy.

[18]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[19]  K. Dickstein,et al.  How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. , 2007, European heart journal.

[20]  J. Cleland,et al.  Defining diastolic heart failure and identifying effective therapies. , 2013, JAMA.

[21]  P. Ponikowski,et al.  Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) , 2010, Journal of cachexia, sarcopenia and muscle.

[22]  J. Cleland,et al.  IVC diameter in patients with chronic heart failure: relationships and prognostic significance. , 2013, JACC. Cardiovascular imaging.

[23]  J. Rouleau,et al.  Prognostic value of the physical examination in patients with heart failure and atrial fibrillation: insights from the AF-CHF trial (atrial fibrillation and chronic heart failure). , 2014, JACC. Heart failure.

[24]  D. Cook,et al.  Clinical assessment of central venous pressure in the critically ill. , 1990, The American journal of the medical sciences.

[25]  R. Davison,et al.  Estimation of central venous pressure by examination of jugular veins. , 1974, American heart journal.

[26]  B. Billah,et al.  B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. , 2010, Archives of internal medicine.

[27]  A. Kaji,et al.  Sonographic assessment of jugular venous distension and B-type natriuretic peptide levels in patients with dyspnoea , 2011, Emergency Medicine Journal.

[28]  A. Jaffe,et al.  Clinical evaluation compared to pulmonary artery catheterization in the hemodynamic assessment of critically ill patients , 1984, Critical care medicine.

[29]  H Ector,et al.  Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. , 2001, The New England journal of medicine.

[30]  J. Cleland,et al.  Update on management of heart failure with preserved ejection fraction , 2015, Current opinion in cardiology.